Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo …
WEB3 days ago · On Friday, Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ: SNY) for $825 million as an upfront payment and additional...
Sanofi’s rare disease drug finds yet another home
WEB4 days ago · Sanofi is selling global rights to Enjaymo to the Italy-based drugmaker Recordati, in exchange for an upfront payment of $825 million. And if the medicine hits certain sales goals, Sanofi could take home up to $250 million more.
Sanofi Drug for Rare Blood Disease Is Heading to Recordati for …
WEB4 days ago · Sanofi’s Enjaymo, the only approved drug therapy for a rare and debilitating blood disorder, is being acquired by Recordati in a deal that helps the Italian company build its rare disease...
In sustained rare disease push, Recordati lays out $825M upfront …
WEB4 days ago · Recordati is floating $825 million upfront—plus another $250 million in potential commercial milestones—to get its hands on the global rights to Sanofi’s rare disease biologic Enjaymo.
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO ...
WEB4 days ago · Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for...
Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 Million
WEB4 days ago · Recordati reached an agreement with French pharmaceutical company Sanofi to acquire the global rights to autoimmune disorder treatment Enjaymo for $825 million.
Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo
WEB4 days ago · Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment specifically targeting cold agglutinin disease (CAD), a rare B-cell...
Press Room - Sanofi US News
WEBJan 25, 2023 · The US Food and Drug Administration (FDA) has approved the expanded indication for Enjaymo ® (sutimlimab-jome), the first and only treatment of hemolysis in adults with cold agglutinin disease (CAD), to include patients with or …
Press Room - Sanofi US News
WEBParis, February 4, 2022. The U.S. Food and Drug Administration (FDA) has approved Enjaymo™ (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).
Sanofi Offloads Rare Autoimmune Drug to Recordati in ... - BioSpace
WEB4 days ago · Sanofi sold Enjaymo, its humanized monoclonal antibody treatment for the rare autoimmune disorder cold agglutinin disease, to Italy’s Recordati in an agreement potentially worth more than $1 billion.
- Some results have been removed